Last reviewed · How we verify
ICP-488 Tablets
ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation.
ICP-488 is a tyrosine kinase inhibitor that targets mutant EGFR and other kinases involved in cancer cell proliferation. Used for Non-small cell lung cancer with EGFR mutations.
At a glance
| Generic name | ICP-488 Tablets |
|---|---|
| Sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
| Drug class | EGFR tyrosine kinase inhibitor |
| Target | EGFR (epidermal growth factor receptor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ICP-488 selectively inhibits epidermal growth factor receptor (EGFR) with activity against common activating mutations and some resistant variants. By blocking EGFR signaling, the drug suppresses downstream pathways that drive proliferation and survival in EGFR-mutant cancers, particularly non-small cell lung cancer.
Approved indications
- Non-small cell lung cancer with EGFR mutations
Common side effects
- Diarrhea
- Rash
- Nausea
- Fatigue
Key clinical trials
- Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study (PHASE2)
- Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis (PHASE2)
- A Clinical Study of ICP-488 in Healthy Subjects and Patients With Psoriasis (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ICP-488 Tablets CI brief — competitive landscape report
- ICP-488 Tablets updates RSS · CI watch RSS
- Beijing InnoCare Pharma Tech Co., Ltd. portfolio CI